<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Pharmacy Blog &#187; Women&#8217;s health</title>
	<atom:link href="http://www.canadiannetmall.com/blog/category/womens-health/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.canadiannetmall.com/blog</link>
	<description></description>
	<lastBuildDate>Sat, 07 May 2011 13:51:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
		<item>
		<title>New Vaginal Estrogen Ring for Menopausal Women</title>
		<link>http://www.canadiannetmall.com/blog/new-vaginal-estrogen-ring-for-menopausal-women/</link>
		<comments>http://www.canadiannetmall.com/blog/new-vaginal-estrogen-ring-for-menopausal-women/#comments</comments>
		<pubDate>Mon, 21 Mar 2011 07:05:39 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Women's health]]></category>
		<category><![CDATA[Menopausal Women]]></category>
		<category><![CDATA[Vaginal Estrogen]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=4565</guid>
		<description><![CDATA[Approximately 75% of menopausal women experience such symptoms as vaginal dryness and temperature fluctuations (&#8220;hot flushes&#8221;). Many women who have taken estrogen tablets or patches still experience vaginal symptoms. The FDA has approved an estradiol acetate vaginal ring (Femring™, Galen), the first vaginal estrogen product that is indicated to treat both the hot flushes and [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/new-vaginal-estrogen-ring-for-menopausal-women/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Women&#8217;s Health Prescription Drugs to Double by 2008</title>
		<link>http://www.canadiannetmall.com/blog/womens-health-prescription-drugs-to-double-by-2008/</link>
		<comments>http://www.canadiannetmall.com/blog/womens-health-prescription-drugs-to-double-by-2008/#comments</comments>
		<pubDate>Thu, 10 Mar 2011 07:05:26 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Women's health]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=4587</guid>
		<description><![CDATA[The worldwide market for prescription drugs for women&#8217;s health is projected to almost double through the year 2007, according to new data released by Kalo-rama Information in New York City. Manufacturers&#8217; revenues for the year 2002 approached $36 billion and are expected to be almost $64 billion by the year 2008. The report reveals that [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/womens-health-prescription-drugs-to-double-by-2008/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Low-Dose Hormonal Patch for Menopausal Symptoms</title>
		<link>http://www.canadiannetmall.com/blog/low-dose-hormonal-patch-for-menopausal-symptoms/</link>
		<comments>http://www.canadiannetmall.com/blog/low-dose-hormonal-patch-for-menopausal-symptoms/#comments</comments>
		<pubDate>Sat, 19 Feb 2011 07:15:29 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Women's health]]></category>
		<category><![CDATA[Low-Dose Hormonal]]></category>
		<category><![CDATA[Menopausal Symptoms]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=4416</guid>
		<description><![CDATA[The FDA has granted marketing approval for a new generic estradiol/levonor-gestrel transdermal (skin patch) system (Climara Pro®) for the treatment of menopausal symptoms. This thin, translucent patch is the first once-weekly combined hormone therapy approved in the U.S. Schering&#8217;s U.S. subsidiary, Berlex, Inc., plans to launch Climara Pro® in January 2004. The transdermal (patch) technology [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/low-dose-hormonal-patch-for-menopausal-symptoms/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fewer Menstrual Periods with New Oral Contraceptive</title>
		<link>http://www.canadiannetmall.com/blog/fewer-menstrual-periods-with-new-oral-contraceptive/</link>
		<comments>http://www.canadiannetmall.com/blog/fewer-menstrual-periods-with-new-oral-contraceptive/#comments</comments>
		<pubDate>Wed, 09 Feb 2011 07:15:09 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Women's health]]></category>
		<category><![CDATA[Menstrual Periods]]></category>
		<category><![CDATA[Oral Contraceptive]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=4436</guid>
		<description><![CDATA[The FDA has approved a new oral contraceptive (Seasonale®, Barr Laboratories) for women. Seasonale® contains a progestin (levonorgestrel) and an estrogen (ethinyl estradiol), which are active ingredients in traditional oral contraceptives. Seasonale® offers a 91-day regimen. Tablets containing the active hormones are taken for 12 weeks (84 days), followed by one week (seven days) of [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/fewer-menstrual-periods-with-new-oral-contraceptive/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Labeling Warning for Contraceptive Patch</title>
		<link>http://www.canadiannetmall.com/blog/labeling-warning-for-contraceptive-patch/</link>
		<comments>http://www.canadiannetmall.com/blog/labeling-warning-for-contraceptive-patch/#comments</comments>
		<pubDate>Sun, 29 Aug 2010 07:37:46 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Women's health]]></category>
		<category><![CDATA[Contraceptive Patch]]></category>
		<category><![CDATA[Labeling Warning]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=3734</guid>
		<description><![CDATA[The FDA has approved updated labeling for Ortho-McNeil&#8217;s contraceptive patch, Ortho Evra®, to warn health care providers and patients that this product exposes women to higher levels ofestrogen than most oral contraceptives. Ortho Evra® was the first skin patch approved for birth control. The patch releases the estrogen hormone ethinyl estradiol and the drug progestin [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/labeling-warning-for-contraceptive-patch/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Extended-Cycle Oral Contraceptive</title>
		<link>http://www.canadiannetmall.com/blog/extended-cycle-oral-contraceptive/</link>
		<comments>http://www.canadiannetmall.com/blog/extended-cycle-oral-contraceptive/#comments</comments>
		<pubDate>Fri, 23 Jul 2010 15:57:40 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Women's health]]></category>
		<category><![CDATA[Oral Contraceptive]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=3560</guid>
		<description><![CDATA[The FDA has approved the NDA for Seasonique (canadian levonorgestrel/ethinyl estradiol 0.15 mg/0.03 mg and ethinyl estradiol 0.01 mg) tablets (Barr Phar-maceuticals/Duramed) to prevent pregnancy. Seasonale, Barr&#8217;s earlier extended-cycle oral contraceptive, was launched in 2003 as a 91-day regimen. Tablets containing the active hormones are taken for 12 weeks (84 days), followed by seven days [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/extended-cycle-oral-contraceptive/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oral Contraceptive (Lybrel) For Continuous Use</title>
		<link>http://www.canadiannetmall.com/blog/oral-contraceptive-lybrel-for-continuous-use/</link>
		<comments>http://www.canadiannetmall.com/blog/oral-contraceptive-lybrel-for-continuous-use/#comments</comments>
		<pubDate>Tue, 11 May 2010 08:08:00 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Women's health]]></category>
		<category><![CDATA[Oral Contraceptive]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=3381</guid>
		<description><![CDATA[Wyeth&#8217;s Lybrel, the first continuous-use oral contraceptive, has been approved. The tablet comes in a 28-day pack with low-dose combination tablets containing 90 mcg of a progestin (generic levo­norgestrel) and 20 mcg of an estrogen (ethinyl estradiol). With the traditional contraceptives, patients take the medication for 21 days, then stop for seven days; the placebo [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/oral-contraceptive-lybrel-for-continuous-use/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

